Phase 2 RCT of 147 patients with resectable thoracic ESCC: neoadjuvant chemoradiation at 50.4 Gy vs 41.4 Gy did not significantly improve 2-year PFS (56.7% vs 49.3%; HR 0.72, 95% CI 0.46-1.11) or OS, and caused more grade ≥2 radiation esophagitis.
RCTn = 147
Yang et al. Randomized Study on Different Radiation Doses in Neoadjuvant Chemoradiation Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (Neo-DRATEC Trial)